Subjects: DOENÇAS HEMATOLÓGICAS, ANTICORPOS MONOCLONAIS, ADULTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEE, Jong Wook et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood, v. 133, n. 6, p. 530-539, 2019Tradução . . Disponível em: https://doi.org/10.1182/blood-2018-09-876136. Acesso em: 23 ago. 2024.APA
Lee, J. W., Fontbrune, F. S. de, Lee, L. W. L., Pessoa, V., Gualandro, S. F. M., Fuereder, W., et al. (2019). Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood, 133( 6), 530-539. doi:10.1182/blood-2018-09-876136NLM
Lee JW, Fontbrune FS de, Lee LWL, Pessoa V, Gualandro SFM, Fuereder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study [Internet]. Blood. 2019 ; 133( 6): 530-539.[citado 2024 ago. 23 ] Available from: https://doi.org/10.1182/blood-2018-09-876136Vancouver
Lee JW, Fontbrune FS de, Lee LWL, Pessoa V, Gualandro SFM, Fuereder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study [Internet]. Blood. 2019 ; 133( 6): 530-539.[citado 2024 ago. 23 ] Available from: https://doi.org/10.1182/blood-2018-09-876136
